Search research articles
Contact Us
Filters
Showing results (31-40 of 58) with videos related to
Page
of 6
Sort By:
Cancer Research
|
October 16, 1999
Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant
K Sturmhoefel, K Lee, G S Gray, et al.
Clinical Immunology (Orlando, Fla.)
|
September 10, 1999
Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein
H Swiniarski, K Sturmhoefel, K Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
October 15, 1996
Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells
B R Blazar, A H Sharpe, P A Taylor, et al.
International Immunology
|
June 1, 1997
The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion
P Rennert, K Furlong, C Jellis, et al.
Protein Expression and Purification
|
April 1, 1991
Expression and purification of active recombinant platelet factor 4 from a cleavable fusion protein
J A Myers, G S Gray, D J Peters, et al.
Immunity
|
September 1, 1994
Absence of B7-dependent responses in CD28-deficient mice
J M Green, P J Noel, A I Sperling, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 1, 1993
Expression and functional significance of an additional ligand for CTLA-4
D J Lenschow, G H Su, L A Zuckerman, et al.
Journal of Neuroimmunology
|
March 1, 1996
Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis
P J Perrin, D Scott, T A Davis, et al.
Blood
|
May 1, 1997
The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties
M W Boyer, D A Vallera, P A Taylor, et al.
Science (New York, N.Y.)
|
January 5, 1990
Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
T E Maione, G S Gray, J Petro, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 58) with videos related to
Sort By:
Page
of 6
Cancer Research
|
October 16, 1999
Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant
K Sturmhoefel, K Lee, G S Gray, et al.
Clinical Immunology (Orlando, Fla.)
|
September 10, 1999
Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein
H Swiniarski, K Sturmhoefel, K Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
October 15, 1996
Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells
B R Blazar, A H Sharpe, P A Taylor, et al.
International Immunology
|
June 1, 1997
The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion
P Rennert, K Furlong, C Jellis, et al.
Protein Expression and Purification
|
April 1, 1991
Expression and purification of active recombinant platelet factor 4 from a cleavable fusion protein
J A Myers, G S Gray, D J Peters, et al.
Immunity
|
September 1, 1994
Absence of B7-dependent responses in CD28-deficient mice
J M Green, P J Noel, A I Sperling, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 1, 1993
Expression and functional significance of an additional ligand for CTLA-4
D J Lenschow, G H Su, L A Zuckerman, et al.
Journal of Neuroimmunology
|
March 1, 1996
Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis
P J Perrin, D Scott, T A Davis, et al.
Blood
|
May 1, 1997
The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties
M W Boyer, D A Vallera, P A Taylor, et al.
Science (New York, N.Y.)
|
January 5, 1990
Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
T E Maione, G S Gray, J Petro, et al.
Page
of 6